[1]
|
Chan, A.K., Cheung, C.W. and Chong, Y.K. (2010) α-Agonist in Acute Pain Management. Expert Opinion on Pharmacotherapy, 11, 2849-2858. https://doi.org/10.1517/14656566.2010.511613
|
[2]
|
Chrysostomou, C. and Schmitt, C.G. (2008) Dexmedetomide: Sedation, Analgesia and Beyond. Expert Opinion on Drug Metabolism & Toxicology, 4, 619-627. https://doi.org/10.1517/17425255.4.5.619
|
[3]
|
Gerlach, A.T. and Dasta, J. (2007) Dexmedetomidine: An Updated Review. Annals of Pharmacotherapy, 41, 245-252.
https://doi.org/10.1345/aph.1h314
|
[4]
|
Hall, J.E., Uhrich, T.D., Barney, J.A., Arain, S.R. and Ebert, T.J. (2000) Sedative, Amnestic and Analgesic Properties of Small-Dose Dexmedetomidine Infusions. Anesthesia & Analgesia, 90, 699-705.
https://doi.org/10.1097/00000539-200003000-00035
|
[5]
|
Nelson, L.E., Lu, J., Guo, T., Saper, C.B., Franks, N.P. and Maze, M. (2003) The α2-Adrenoceptor agonist Dexmedetomidine Converges on an Endogenous Sleep Promoting Pathway to Exert Its Sedative Effects. Anesthesiology, 98, 428-436. https://doi.org/10.1097/00000542-200302000-00024
|
[6]
|
Upton, R.N., Somogyi, A.A., Martinez, M., Colvill, J. and Grant, C. (2010) Pharmacokinetics and Pharmacodynamics of the Short-Acting Sedative CNS 7056 in Sheep. British Journal of Anaesthesia, 105, 798-809.
https://doi.org/10.1093/bja/aeq260
|
[7]
|
Liu, Y., Xu, X., Xie, J., Ma, H., Wang, T., Zhang, G., et al. (2016) Design, Synthesis, and Biological Evaluation of Novel CNS 7056 Derivatives as Sedatives in Rats and Rabbits. Chemical Biology & Drug Design, 88, 38-42.
https://doi.org/10.1111/cbdd.12731
|
[8]
|
Antonik, L.J., Goldwater, D.R., Kilpatrick, G.J., Tilbrook, G.S. and Borkett, K.M. (2012) A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinefics, and Pharmacodynamics of Remimazolam (CNS 7056): PartI. Safety, Efficacy, and Basic Pharrnacokinetics. Anesthesia & Analgesia, 115, 274-283. https://doi.org/10.1213/ane.0b013e31823f0c28
|
[9]
|
WiItshire, H.R., Kilpatrick, G.J., Tilbrook, G.S. and Borkett, K.M. (2012) A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part II. Population Pharrnacokinetic and Pharmacodynamic Modeling and Simulation. Anesthesia & Analgesia, 115, 284-296. https://doi.org/10.1213/ane.0b013e318241f68a
|
[10]
|
Worthington, M.T., Antonik, L.J., Goldwater, D.R., Lees, J.P., Wilhelm-Ogunbiyi, K., Borkett, K.M., et al. (2013) A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing Colonoscopy. Anesthesia & Analgesia, 117, 1093-1100. https://doi.org/10.1213/ane.0b013e3182a705ae
|
[11]
|
Florio, P., Puzzutiello, R., Filippeschi, M., D’Onofrio, P., Mereu, L., Morelli, R., et al. (2012) Low-Dose Spinal Anesthesia with Hyperharic Bupivacaine with Intrathecal Fentanyl for Operative Hysteroscopy: A Case Series Study. Journal of Minimally Invasive Gynecology, 19, 107-112. https://doi.org/10.1016/j.jmig.2011.08.728
|
[12]
|
Borkett, K.M., Riff, D.S., Schwartz, H.I., Winkle, P.J., Pambianco, D.J., Lees, J.P., et al. (2015) A Phase IIa, Randomized, Double. Blind Study of Remimazolam (CNS 7056) versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy. Anesthesia & Analgesia, 120, 771-780. https://doi.org/10.1213/ane.0000000000000548
|